Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?
Open Access
- 1 July 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 11 (7), 790-800
- https://doi.org/10.1634/theoncologist.11-7-790
Abstract
Learning Objectives: After completing this course, the reader will be able to: Describe the epidemiologic trend of HCC.Discuss the inherent difficulty and challenge of developing systemic therapy for HCC.Outline the history and current status of systemic therapy for HCC.Describe the rationale and current status of developing molecularly targeted agents for HCC. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com Worldwide, hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death. In the U.S., 18,510 new cancers of the liver and intrahepatic bile duct are expected in 2006, with an estimated 16,200 deaths. The incidence rates for HCC in the U.S. continued to rise steadily through 1998 and doubled during the period 1975–1995. Unresectable or metastatic HCC carries a poor prognosis, and systemic therapy with cytotoxic agents provides marginal benefit. A majority of HCC patients (>80%) presents with advanced or unresectable disease. Even for those with resected disease, the recurrence rate can be as high as 50% at 2 years. Because of the poor track record of systemic therapy in HCC, there has been a sense of nihilism for this disease in the oncology community for decades. However, with the arrival of newly developed molecularly targeted agents and the success of some of these agents in other traditionally challenging cancers, like renal cell carcinoma, there has recently been renewed interest in developing systemic therapy for HCC. This review attempts to concisely summarize the historical perspective and the current status of systemic therapy development in HCC.Keywords
This publication has 92 references indexed in Scilit:
- A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular CarcinomaJNCI Journal of the National Cancer Institute, 2005
- A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular CarcinomaThe Oncologist, 2005
- Thalidomide in the treatment of patients with hepatocellular carcinomaCancer, 2005
- Phase II study of thalidomide in patients with unresectable hepatocellular carcinomaCancer, 2004
- Natural history of inoperable hepatocellular carcinoma: Estrogen receptors' status in the tumor is the strongest prognostic factor for survivalHepatology, 2000
- The Hallmarks of CancerCell, 2000
- Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanismJournal of Hepatology, 1995
- Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patientsGastroenterology, 1995
- Controlled trial of tamoxifen in patients with advanced hepatocellular carcinomaJournal of Hepatology, 1994
- Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifenJournal of Hepatology, 1990